rs3825016 — SLC22A12

Synonymous coding variant in the URAT1 renal urate transporter; the C allele is associated with increased urate reabsorption and 27% higher odds of hyperuricemia, completing the URAT1 genetic panel alongside rs505802 (promoter) and rs121907892 (W258X)

Moderate Risk Factor Share

Details

Gene: SLC22A12
Chromosome: 11
Risk allele: C
Clinical: Risk Factor
Evidence: Moderate

Population Frequency

22%

50%

28%

External

SNPedia ClinVar dbSNP

See your personal result for SLC22A12

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

SLC22A12 rs3825016 — The URAT1 Exonic Variant That Modulates Urate Reabsorption Risk

Every molecule of uric acid your body produces eventually reaches the kidney, where it must run a gauntlet of transporters that shuttle it between the blood and the urine. The most important of these is URAT1¹¹ URAT1
Urate Anion Transporter 1, encoded by SLC22A12 — the primary apical exchanger in proximal tubule cells that drives ~90% of renal urate reabsorption. The rs3825016 variant sits inside the SLC22A12 coding sequence at position 258 of the mRNA (NM_144585.4:c.258C>T), causing a synonymous change at codon 86 — the reference CAC (histidine) becomes CAT, still encoding histidine (p.His86=). The protein sequence is identical regardless of genotype, yet the C allele is robustly associated with elevated serum uric acid and hyperuricemia across multiple populations.

This positions rs3825016 as the third member of a natural URAT1 genetic panel: rs505802 (upstream promoter, sets overall URAT1 expression level) and rs121907892 W258X (truncating loss-of-function, causes severe hypouricemia) define the extremes of URAT1 activity, while rs3825016 captures a coding-region signal that operates through a mechanism independent of those two variants.

The Mechanism

Synonymous variants are no longer treated as automatically silent. A synonymous change can alter mRNA secondary structure²² mRNA secondary structure
Changes in local mRNA folding can affect ribosome pausing and translational elongation speed, which in turn affects co-translational protein folding, codon usage³³ codon usage
Certain synonymous codons are read more slowly by the ribosome because the matching tRNA is less abundant — this changes the folding and membrane integration of multi-pass transmembrane proteins like URAT1, or create cryptic splice sites. URAT1 is a twelve-pass transmembrane protein with complex topology; synonymous variation near transmembrane domains 2–3 (where His86 resides) could plausibly influence transporter surface expression or turnover without altering the primary sequence.

Alternatively, rs3825016 may be in linkage disequilibrium with a nearby regulatory or functional variant that is the true causal allele. The SLC22A12 locus harbors several variants in varying LD, including the rs505802 promoter haplotype (r² varies by ethnicity). In Han Chinese populations, rs3825016 and rs475688 are both genotyped as part of URAT1 risk panels, suggesting partial LD and potentially additive effects at the locus level.

The Evidence

Meta-analyses of hyperuricemia and gout: Zou et al. (2018)⁴⁴ Zou et al. (2018)
Zou Y et al. Associations between the SLC22A12 gene and gout susceptibility: a meta-analysis. Clin Exp Rheumatol, 2018 pooled 7 studies (1,216 cases, 1,844 controls) and found the C allele was associated with hyperuricemia in the allelic comparison (OR 1.274, 95% CI 1.101–1.474, p = 0.001). This was confirmed and extended in a larger synthesis by Zheng et al. (2022)⁵⁵ Zheng et al. (2022)
Zheng Q et al. Genetic Association Between SLC22A12 Variants and Susceptibility to Hyperuricemia: A Meta-Analysis. Genet Test Mol Biomarkers, 2022, which pooled 20 studies (4,817 cases, 6,819 controls) and confirmed significant association under allelic and dominant models.

Pharmacogenomics — losartan uricosuric response: Sun et al. (2015)⁶⁶ Sun et al. (2015)
Sun H et al. URAT1 gene polymorphisms influence uricosuric action of losartan in hypertensive patients with hyperuricemia. Pharmacogenomics, 2015 studied 101 hypertensive patients with hyperuricemia and found that the CT mutant genotype was significantly more frequent in patients (32.7%) than healthy controls (18.8%, p = 0.02). Patients with the CT genotype showed a blunted serum uric acid reduction in response to losartan compared with CC carriers, suggesting that rs3825016 influences how effectively URAT1-mediated urate reabsorption responds to this antihypertensive drug's uricosuric action. Wu et al. (2021)⁷⁷ Wu et al. (2021)
Wu L et al. The impact of a URAT1 polymorphism on the losartan treatment of hypertension and hyperuricemia. J Clin Lab Anal, 2021 independently replicated this finding (CT more frequent in patients vs controls: 36.9 vs 21.5%, p = 0.03).

Multi-locus gout prediction: Tu et al. (2018)⁸⁸ Tu et al. (2018)
Tu HP et al. Variants of ALPK1 with ABCG2, SLC2A9, and SLC22A12 increased the positive predictive value for gout. J Hum Genet, 2018 demonstrated that adding rs3825016 CC to a panel of ALPK1, ABCG2, and SLC2A9 risk alleles raised the positive predictive value for gout to 99% (OR 55) in Han Chinese. This highlights the additive contribution of rs3825016 within the urate network even though its individual effect size is modest.

Practical Actions

The CC genotype produces the highest C-allele burden at this locus. For individuals with this genotype — especially those of East Asian or African ancestry where CC is the majority genotype — the URAT1 genetic risk from rs3825016 compounds with contributions from the SLC22A12 promoter (rs505802) and the major urate transport genes SLC2A9 and ABCG2. The practical implication is early urate monitoring before symptoms develop. Dietary purines and fructose add a modifiable layer on top of the genetic baseline.

The losartan pharmacogenomics finding has direct clinical relevance: hypertensive patients with the CT genotype may need a higher dose or different drug to achieve uricosuric benefit — this should be discussed with prescribers.

Interactions

rs505802 (SLC22A12 promoter) and rs121907892 (W258X): These three SLC22A12 variants tag different aspects of URAT1 biology. rs505802 modulates URAT1 expression quantity; rs3825016 is a coding-region signal (possibly affecting transporter folding or in LD with a causal variant); rs121907892 W258X abolishes function entirely. Individuals carrying the rs505802 CC and rs3825016 CC genotypes together have additive URAT1-mediated urate reabsorption risk from two independent loci in the same gene.

SLC2A9 (rs3733591) and ABCG2 (rs2231142): The three major urate handling genes — SLC22A12 (URAT1, apical reabsorption), SLC2A9 (GLUT9, basolateral reabsorption), and ABCG2 (BCRP, apical secretion) — operate at independent points in renal urate handling. Risk alleles at all three loci are additive; the Tu et al. 2018 multi-locus analysis demonstrated that stacking rs3825016 CC onto ABCG2 and SLC2A9 risk genotypes raises gout positive predictive value to near certainty.

ALPK1 (rs11726117): The kinase ALPK1 is a trans-regulator of URAT1 protein expression. Kuo et al. 2017 found that the ALPK1 rs11726117 T allele reduces gout risk partly through its suppression of URAT1 at the rs3825016 and rs475688 loci (OR 0.39 in gout cases). This suggests ALPK1 acts upstream of SLC22A12 transcription; individuals with both risk genotypes at ALPK1 and SLC22A12 may have additive URAT1 activity.

Drug Interactions

losartan reduced_efficacy literature

Nutrient Interactions

purine altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant:

TT “Protective URAT1 Variant” Normal

Two protective T alleles — lower URAT1-associated urate reabsorption risk

The TT genotype is the low-risk state at this locus. In the Zou et al. 2018 meta-analysis, the T allele was the reference allele for protective effects — C allele carriers showed OR 1.27 for hyperuricemia, meaning TT carriers have the baseline (lower) risk. While the mechanism remains under investigation — this is a synonymous variant, so the protein sequence is unchanged — the consistent association across multiple populations suggests the T allele either directly affects URAT1 expression or marks a protective haplotype at the SLC22A12 locus. For Europeans, TT is the plurality genotype and represents the typical European URAT1 risk profile.

CT “Intermediate URAT1 Risk” Intermediate Caution

One C risk allele — moderately increased hyperuricemia susceptibility

As a CT heterozygote, your rs3825016 C allele contributes modestly to urate reabsorption risk. Studies of this variant in hypertensive patients with hyperuricemia found that the CT genotype was significantly more frequent in affected patients than in healthy controls (Sun et al. 2015: 32.7 vs 18.8%; Wu et al. 2021: 36.9 vs 21.5%), suggesting it tags a genuine functional state rather than random association noise. The pharmacogenomic finding — that CT carriers show reduced serum uric acid lowering from losartan — has direct clinical relevance if you take this medication for hypertension.

In multivariate models, the CT genotype is the middle state: it contributes one C allele's worth of URAT1 risk. For most CT carriers without other genetic risk factors, the risk is low enough that routine lifestyle awareness is sufficient. Additional genetic or metabolic co-factors (obesity, metabolic syndrome) compound the modest elevation from one C allele.

CC “Elevated URAT1 Risk” High Risk Warning

Two C risk alleles — highest URAT1-associated hyperuricemia susceptibility at this locus

The CC homozygous state at rs3825016 represents the maximum URAT1 risk conferred by this coding variant. The Zou et al. 2018 meta-analysis reported OR 1.274 per allele in the allelic model; under a multiplicative model, two alleles approximately compound to OR ~1.6. In the Tu et al. 2018 multi-locus panel, rs3825016 CC was one of four allele combinations that together raised gout positive predictive value to 99% in Han Chinese, demonstrating its importance in the East Asian genetic architecture of hyperuricemia.

The pharmacogenomics implication is directly actionable: hypertensive CC carriers in the Sun et al. 2015 and Wu et al. 2021 studies showed reduced effectiveness of losartan's uricosuric action compared with CC wild-type patients. This is potentially paradoxical (since CC here is the risk allele, not the wild-type), but reflects that the C allele at rs3825016 does not map cleanly onto simple "more transporter = more inhibition" pharmacodynamics — the mechanism may involve altered transporter topology or mRNA processing rather than increased URAT1 surface expression per se.

Regular serum uric acid monitoring and dietary purine reduction are the cornerstones of management. If urate remains elevated above 7 mg/dL despite dietary modification, pharmacological urate-lowering therapy should be discussed with a physician.